An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

Trial Profile

An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Heart failure
  • Focus Diagnostic use
  • Sponsors GE Healthcare
  • Most Recent Events

    • 02 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to the United Kingdom Clinical Research Network record.
    • 02 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top